This article was originally published in The Rose Sheet
Executive SummaryProfessional and Cosmetics & Fragrances division combined sales increased 5.3% to $2.68 bil. (€1=$1.20) after adjustment for the year ended June 30, German firm announces Sept. 28. On a nominal basis, revenues of the businesses decreased 8.5% due to "changes in the scope of consolidation." Cosmetics & Fragrances division sales grew 6.2% after adjustment to $983.7 mil. In nominal terms, revenues fell 7.2% as a result of the sale of the North American subsidiary to Procter & Gamble, firm notes. Division's earnings before interest and taxes were $131.3 mil., an increase of 44.3%. Sales of the Professional division were up 4.7% to $1.7 bil. after adjustment for consolidation and currency effects. Wella notes the sales of its consumer business to P&G is almost complete...
You may also be interested in...
Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.
The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.